Alteraciones del perfil lipídico y renal ocasionados por la terapia antirretroviral en pacientes con VIH-SIDA en el Hospital Isidro Ayora

HIV/AIDS is one of the diseases that currently represents a great challenge in the field of health, and the establishment of antiretroviral treatment that has been one of the fundamental pillars in improving the quality of life in patients with HIV, despite this the administration also leads metabolic changes, among the most common are dyslipidemias and increased creatinine, associated not only with the presence of the virus but also with the different retrovirals used. The following study had a quantitative approach and a nonexperimental design with a longitudinal section. The general objective was to establish the alterations in the lipid and renal profile caused by the three different antiretroviral regimens in patients with HIV/AIDS who go the Isidro Ayora General Hospital. The analytical determination of the lipid and renal profile was carried out in the UV-1100 spectrophotometer through the enzymatic colorimetric method. For the analysis and presentation of the results, the statistical program "IBM SPSS Statistics" was used, where the variance homogeneity test was performed, identifying parametric and non-parametric data. For the parametric data, the Anova test was used with a post hoc of the Schaffé method and for non-parametric data, the Kruskal Wallis test. The lipid and renal profiles of 140 patients were analyzed, finding first that the most frequent therapies were: tenofovir/lamivudine/dolutegravir, abacavir/lamivudine+dolutegravir and tenofovir/emtricitabine+dolutegravir, respectively. Once the statistical tests were applied, a significant increase in cholesterol levels was found in the lipid profile of patients with abacavir/lamivudine/dolutegravir; while, in the renal profile, the concentrations of urea and creatinine increased in the patients with tenofovir/emtricitabine/dolutegravir. In this way it was concluded that the schemes with abacavir/lamivudine/dolutegravir and tenofovir/emtricitabine/dolutegravir are the types of treatment that cause the greatest metabolic alterations at the lipid and renal levels, respectively

• Autor Principal: Chamba Correa, Dayana Mishell (author)
• Formato: bachelorThesis
• Idioma: spa
• Publicado: 2022
• Subjects: LABORATORIO CLÍNICO; PRUEBAS BIOQUÍMICAS; DISLIPIDEMIAS; ESPECTROFOTOMETRÍA
• Acceso en liña: https://dspace.unl.edu.ec/jspui/handle/123456789/25335